AR038603A1 - PIRIDIN ETHANOLAMINE SALT AND ITS USE AS A BETA-3-ADRENERGIC RECEIVER AGONIST - Google Patents

PIRIDIN ETHANOLAMINE SALT AND ITS USE AS A BETA-3-ADRENERGIC RECEIVER AGONIST

Info

Publication number
AR038603A1
AR038603A1 ARP030100606A ARP030100606A AR038603A1 AR 038603 A1 AR038603 A1 AR 038603A1 AR P030100606 A ARP030100606 A AR P030100606A AR P030100606 A ARP030100606 A AR P030100606A AR 038603 A1 AR038603 A1 AR 038603A1
Authority
AR
Argentina
Prior art keywords
salt
monohydrate
beta
piridin
ethanolamine salt
Prior art date
Application number
ARP030100606A
Other languages
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR038603A1 publication Critical patent/AR038603A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Sal de tosilato de (R)-2-(2-(4-oxazol-4-ilfenoxi)etilamino)-1piridin-3-iletanol), el monohidrato de dicha sal, procedimientos útiles en la preparación de dicha sal y dicho monohidrato, composiciones farmacéuticas que comprenden dicha sal, o dicho monohidrato, procedimientos para tratar enfermedades, afecciones y trastornos en un mamífero mediados por el receptor beta3 adrenérgico utilizando dicha sal, monohidrato o dichas composiciones farmacéuticas; y procedimientos para aumentar el contenido de carne magra en animales comestibles utilizando dicha sal, dicho monohidrato o dichas composiciones farmacéuticas.(R) -2- (2- (4-oxazol-4-ylphenoxy) ethylamino) -1-pyridin-3-yletanol) tosylate salt, the monohydrate of said salt, processes useful in the preparation of said salt and said monohydrate, pharmaceutical compositions comprising said salt, or said monohydrate, methods for treating diseases, conditions and disorders in a mammal mediated by the beta-adrenergic receptor using said salt, monohydrate or said pharmaceutical compositions; and methods for increasing the content of lean meat in edible animals using said salt, said monohydrate or said pharmaceutical compositions.

ARP030100606A 2002-02-27 2003-02-25 PIRIDIN ETHANOLAMINE SALT AND ITS USE AS A BETA-3-ADRENERGIC RECEIVER AGONIST AR038603A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36024802P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
AR038603A1 true AR038603A1 (en) 2005-01-19

Family

ID=27766205

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100606A AR038603A1 (en) 2002-02-27 2003-02-25 PIRIDIN ETHANOLAMINE SALT AND ITS USE AS A BETA-3-ADRENERGIC RECEIVER AGONIST

Country Status (8)

Country Link
AR (1) AR038603A1 (en)
AU (1) AU2003248355A1 (en)
GT (1) GT200300044A (en)
PA (1) PA8567601A1 (en)
PE (1) PE20030900A1 (en)
TW (1) TW200305414A (en)
UY (1) UY27678A1 (en)
WO (1) WO2003072571A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
CA2423792A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
PA8567601A1 (en) 2003-12-10
PE20030900A1 (en) 2003-10-25
UY27678A1 (en) 2003-10-31
AU2003248355A1 (en) 2003-09-09
GT200300044A (en) 2003-09-22
WO2003072571A1 (en) 2003-09-04
TW200305414A (en) 2003-11-01

Similar Documents

Publication Publication Date Title
UY28933A1 (en) COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS
ECSP10010684A (en) MIXED AGONISTS, BASED ON GIP FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY.
BRPI0817693A2 (en) Methods and apparatus for illuminating eggs by means of detecting the embryo's heartbeat
HN2008001720A (en) ARILIMIDAZOLONAS AND ARILTRIAZOLONAS REPLACED AS INHIBITORS OF VASOPRESINE RECEPTORS
EA201001256A1 (en) DERIVATIVES OF DIAZASPIRO [5.5] UNDECKAN AS ANTAGONISTS OF MUSCARIN RECEPTORS AND BETA ADRENORECEPTOR AGONISTS FOR PULMONARY DISEASES
ECSP077421A (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER 1
HN2006007884A (en) OXYINDOL DERIVATIVES
CR8642A (en) COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN THE TREATMENT OF METABOLIC DISORDERS
CL2012002497A1 (en) Compounds derived from imidazopyrimidine, substituted, pde10a inhibitors; preparation procedure; pharmaceutical composition; and its use for the treatment or prevention of psychotic disorders, schizophrenia, parkinson's disease, multiple sclerosis, among others.
UY30477A1 (en) DERIVATIVES OF [4,5 '] BIPIRIMIDINIL-6,4´-DIAMINE AS PROTEIN KINASE INHIBITORS
CL2007001451A1 (en) Compounds derived from [1,2,3] -thiazol-4-ylmethoxy, farnesoid receptor agonist x (fxr); pharmaceutical composition comprising said compounds; and its use to treat dyslipidemia and related diseases.
WO2005121065A3 (en) DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS
NO20063620L (en) Arylaniline derivatives as beta2 adrenergic receptor agonists
ECSP067021A (en) COMPOUNDS AND COMPOSITIONS AS RECEPTOR MODULATORS ACTIVATED BY PEROXISOM PROLIFERATOR (PPAR)
DOP2010000304A (en) COMPOSITIONS AND METHODS OF PREPARATION AND USE OF THE SAME
CL2008002793A1 (en) Compounds derived from substituted amides, inhibitors of btk activity; pharmaceutical composition comprising them; Useful in the treatment of cancer, bone disorders, autoimmune diseases, among others
CY1110922T1 (en) COMPETITIVES OF GLUCAGON COMPETITORS, PREPARATION AND HEALTH USES
ATE469897T1 (en) INDAZOLE CARBONIC ACID AMIDE COMPOUNDS
BRPI0608012A2 (en) cancer treatment method, nk cell activity increase method, innate th1 response or activity increase method, method of treatment of a th2-mediated dysfunction, method of treatment of an immune disease, uses of an antagonist molecule and use of an agonist molecule
NI200900081U (en) TRKB AGONIST ANTIBODIES AND THEIR USES.
DE602005016446D1 (en) 5-HT4 receptor agonist compounds
CL2007003065A1 (en) Compounds derived from benzodioxane, 5ht2c agonist, pharmaceutical composition that you understand; and its use in the treatment of a psychotic disorder, anxiety, depression, bipolar disorder, premenstrual syndrome, among others
CL2007002971A1 (en) COMPOUNDS DERIVED FROM AMINOMETIL-4-IMIDAZOL; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM; AND ITS USE TO TREAT DEPRESSION, ANXIETY, BIPOLAR DISORDER, AMONG OTHERS.
DK1719507T3 (en) Beta-2 adrenoceptor agonists for the treatment of connective tissue disorders of the skin
ECSP088584A (en) NEW DERIVATIVES OF BENZIMIDAZOL AS INHIBITORS OF VANILLOID RECEIVER 1 (VRL)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal